13 completed, 4 terminated, 3 active not recruiting, 3 unknown. 18 Phase 2, 6 Phase 1, 6 Phase 3, 2 Not applicable.
Follow HER-2 Positive Breast Cancer: new trials by email Literature Review of HER-2 Positive Breast Cancer trials Research Report on HER-2 Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer Resistant Potato Starch, Placebo control - Breast Cancer, HER-2 Positive Breast Cancer | Not applicable | Not yet recruiting | University of Vermont Medical Center | 12 | 2027-10-01 | 2026-02-12 |
| Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) Lipo-Dox®, Cyclophosphamide, Trastuzumab (Herceptin) - HER-2 Positive Breast Cancer | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 54 | 2026-04-30 | 2026-05-04 |
| Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy - Breast Cancer - Infiltrating Ductal Carcinoma, HER-2 Positive Breast Cancer | Phase 2 | Recruiting | Legacy Health System | 30 | 2026-04-27 | 2026-05-01 |
| A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer TCbHP VS ddEC-THP - HER-2 Positive Breast Cancer | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 832 | 2022-10-08 | 2023-05-23 |
| PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study Efficacy of the Pertuzumab-Trastuzumab combination - HER-2 Positive Breast Cancer | Unknown | Hospices Civils de Lyon | 200 | 2020-12-01 | 2020-11-25 | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer palbociclib, trastuzumab, pertuzumab - HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer | Phase 3 | Active not recruiting | Alliance Foundation Trials, LLC. | 518 | 2017-06-21 | 2026-10-22 |
| A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer Abemaciclib, Trastuzumab, Fulvestrant - Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Eli Lilly and Company | 237 | 2016-05-23 | 2024-11-26 |
| Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer nab-paclitaxel, Trastuzumab - Breast Cancer, Estrogen Receptor Negative Neoplasm | Phase 2 | Terminated | Osaka Medical College | 30 | 2015-11-01 | 2019-08-28 |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Margetuximab, Trastuzumab, Physician's choice of chemotherapy. - HER-2 Positive Breast Cancer, Metastatic Neoplasm | Phase 3 | Completed | MacroGenics | 624 | 2015-08-24 | 2025-03-17 |
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA T-DM1, Pertuzumab, Excision of tumor/mastectomy - HER-2 Positive Breast Cancer, Breast Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 164 | 2015-01-01 | 2026-10-02 |
| A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer Liposomal doxorubicin, Docetaxel, Trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 49 | 2014-12-17 | 2025-02-03 |
| Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer docetaxel + trastuzumab sc + pertuzumab, trastuzumab emtansin - Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer | Phase 2 / Phase 3 | Active not recruiting | Thomas Hatschek | 202 | 2014-11-01 | 2020-08-13 |
| Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Ruxolitinib, Trastuzumab - Metastatic Breast Cancer, Breast Carcinoma | Phase 1 / Phase 2 | Completed | Dawn L. Hershman | 32 | 2014-06-01 | 2023-08-24 |
| Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Tesevatinib, Trastuzumab - HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain | Phase 1 / Phase 2 | Terminated | Kadmon Corporation, LLC | 17 | 2014-05-01 | 2022-04-27 |
| Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer Trastuzumab, Weekly Paclitaxel, Carboplatin - Breast Cancer, HER-2 Positive Breast Cancer | Not applicable | Withdrawn | Instituto do Cancer do Estado de São Paulo | 2014-04-01 | 2016-08-31 | |
| Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) nab-Paclitaxel, Paclitaxel - Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II | Phase 3 | Completed | GBG Forschungs GmbH | 1229 | 2012-07-01 | 2020-08-06 |
| An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer ganetespib - Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Synta Pharmaceuticals Corp. | 51 | 2012-07-01 | 2015-11-05 |
| HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 T-DM1, 89Zr-trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | Jules Bordet Institute | 90 | 2012-05-01 | 2025-03-31 |
| A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases Everolimus, Vinorelbine, Trastuzumab - HER-2 Positive Breast Cancer | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 32 | 2011-09-01 | 2018-12-17 |
| Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab Nab-paclitaxel - Breast Cancer, HER-2 Positive Breast Cancer | Phase 2 | Completed | Osaka Medical College | 46 | 2011-09-01 | 2015-04-22 |
Showing 20 of 28. Sign in to see all of them.
Breast Neoplasms (17) · Brain Neoplasms (2) · Carcinoma, Ductal, Breast (2) · Inflammatory Breast Neoplasms (2) · Pathologic Complete Response (2) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (21) · Neoplasms by Site (20) · Breast Diseases (19) · Skin Diseases (19) · Skin and Connective Tissue Diseases (19) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Adenocarcinoma (2) · Brain Diseases (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Ductal (2) · Central Nervous System Diseases (2) · Central Nervous System Neoplasms (2) · Disease Attributes (2)
Trastuzumab (14) · Paclitaxel (5) · Carboplatin (4) · pertuzumab (4) · 130-nm albumin-bound paclitaxel (3) · Ado-Trastuzumab Emtansine (3) · Albumin-Bound Paclitaxel (3) · Docetaxel (2) · Doxorubicin (2) · Fulvestrant (2) · Lapatinib (2) · liposomal doxorubicin (2) · 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide (1) · Anastrozole (1) · Bevacizumab (1)
GBG Forschungs GmbH (2) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (2) · Osaka Medical College (2) · Alliance Foundation Trials, LLC. (1) · Asociación para el Progreso de la Oncología en Málaga (1) · Dana-Farber Cancer Institute (1) · Dawn L. Hershman (1) · Eli Lilly and Company (1) · Hospices Civils de Lyon (1) · Instituto do Cancer do Estado de São Paulo (1) · Jules Bordet Institute (1) · Kadmon Corporation, LLC (1) · Legacy Health System (1) · Lucia Del Mastro,MD (1) · MacroGenics (1)
United States (12) · Italy (7) · Belgium (5) · Germany (5) · Spain (5) · France (4) · Australia (3) · Brazil (3) · Netherlands (3) · South Korea (3) · United Kingdom (3) · Argentina (2) · Canada (2) · China (2) · Japan (2)
Mitsuhiko Iwamoto, MD, PhD (2) · Adrienne Waks, MD (1) · Anna Fedeli, MD (1) · Carey K Anders, MD (1) · Dawn Hershman, MD, MS (1) · Debora de Gagliato, MD (1) · Dino Amadori, MD (1) · Emilio Alba (1) · Gunter von Minckwitz, MD, Prof (1) · Jonas Bergh, Professor (1) · Lee Schwartzberg, MD, FACP (1) · Lucia Del Mastro, MD (1) · Max Se Mano, MD phD (1) · Michael Untch, Prof MD (1)
PMID 12954578, PMID 24794243, PMID 25199759, PMID 25524798, PMID 25534375, PMID 25579459, PMID 26598545, PMID 26869049, PMID 28315068, PMID 28341957, PMID 28715532, PMID 29938395, PMID 30963212, PMID 32353342, PMID 33369581, PMID 33480963, PMID 34165503, PMID 34252375, PMID 36332179, PMID 36449695, PMID 37014668, PMID 37906649, PMID 38175448, PMID 38300710, PMID 41543393, PMID 41604639
2009 (1), 2015 (1), U01CA168426 (1)